Oral Therapy

Novartis Investigational Oral Therapy Iptacopan (Lnp023) Shows Benefit as Monotherapy in Treatment-Naïve Patients with Rare and Life-threatening Blood Disorder Paroxysmal Nocturnal Hemoglobinuria

Novartis

COVID-19 Treatment

Novartis and Molecular Partners Announce Start of EMPATHY Clinical Trial for Ensovibep for the Treatment of COVID-19

Novartis

FDA Approval

Novartis Cosentyx Receives FDA Approval for Treatment of Children and Adolescents with Moderate to Severe Plaque Psoriasis

Novartis

Production

Novartis to Produce Roche's Actemra/RoActemra

Novartis

Novartis Announces Collaboration with Molecular Partners to Develop Two DARPin Therapies for Potential Use Against COVID-19

Novartis

Antibiotics

Sandoz Announces Plans for Joint Investment to Help Strengthen Future of Antibiotics Manufacturing in Europe

Sandoz

Novartis Launches First-of-its-Kind Not-for-Profit Portfolio of Medicines for Symptomatic Treatment of COVID-19

Novartis

FDA Approval

Novartis Announces FDA Approval of MET Inhibitor Tabrecta™ for Metastatic Non-Small Cell Lung Cancer with METex14

Novartis

M&A

Novartis Acquires Amblyotech

Novartis

COVID-19 Clinical Trials

Novartis to Sponsor Large Clinical Trial of Hydroxychloroquine in Hospitalized COVID-19 Patients

Novartis

COVID-19 Clinical Study

Novartis Announces Plans to Initiate Clinical Study of Jakavi in Severe COVID-19 Patients

Novartis

Priority Review

Novartis Lung Cancer Drug Granted Priority FDA Review

Novartis

M&A

Novartis to Acquire The Medicines Company for $9.7 Billion

Novartis

Approval

Novartis Gets European Approval to Update Cosentyx Label to Include Dosing Flexibility in Ankylosing Spondylitis

Novartis

Collaboration

Novartis and Microsoft Announce Collaboration to Transform Medicine with Artificial Intelligence

Novartis

Novartis Stands Behind Zolgensma® (onasemnogene abeparvovec-xioi) for the Treatment of Children Less than 2 Years of Age with Spinal Muscular Atrophy

Novartis

FDA Acceptance

FDA Accepts File and Accelerates Review of Novartis Sickle Cell Disease Medicine Crizanlizumab (SEG101)

Novartis